Austin Health

Title
Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.
Publication Date
2022-06-06
Author(s)
Cilento, Michael A
Klein, Oliver
Egan, Elizabeth
Roberts-Thomson, Rachel
Subject
cancer intervention
chemotherapy
dermatology
immunology
skin cancer
oncology
Type of document
Journal Article
OrcId
https://orcid.org/0000-0003-0022-9553
DOI
10.1111/ajd.13881
Abstract
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).
Link
Citation
The Australasian Journal of Dermatology 2022; 63(3): e222-e225
Jornal Title
The Australasian Journal of Dermatology

Files:

NameSizeformatDescriptionLink